First Time Loading...

Cidara Therapeutics Inc
NASDAQ:CDTX

Watchlist Manager
Cidara Therapeutics Inc Logo
Cidara Therapeutics Inc
NASDAQ:CDTX
Watchlist
Price: 12.61 USD 0.8%
Updated: May 6, 2024

Cidara Therapeutics Inc
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cidara Therapeutics Inc
Net Income (Common) Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Cidara Therapeutics Inc
NASDAQ:CDTX
Net Income (Common)
-$22.9m
CAGR 3-Years
33%
CAGR 5-Years
20%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Income (Common)
$4.8B
CAGR 3-Years
2%
CAGR 5-Years
-3%
CAGR 10-Years
2%
Gilead Sciences Inc
NASDAQ:GILD
Net Income (Common)
$484m
CAGR 3-Years
17%
CAGR 5-Years
-39%
CAGR 10-Years
-20%
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$6.7B
CAGR 3-Years
-3%
CAGR 5-Years
-4%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income (Common)
$3.6B
CAGR 3-Years
10%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income (Common)
$4B
CAGR 3-Years
4%
CAGR 5-Years
10%
CAGR 10-Years
25%

See Also

What is Cidara Therapeutics Inc's Net Income (Common)?
Net Income (Common)
-22.9m USD

Based on the financial report for Dec 31, 2023, Cidara Therapeutics Inc's Net Income (Common) amounts to -22.9m USD.

What is Cidara Therapeutics Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
20%

Over the last year, the Net Income (Common) growth was 23%. The average annual Net Income (Common) growth rates for Cidara Therapeutics Inc have been 33% over the past three years , 20% over the past five years .